进展期胃癌术后腹腔化疗的临床疗效分析  

Evaluate for the effect of intraperitoneal chemotherapy for patients with postoperative gastric carcinoma

作　　者：郭锰[1] 

机构地区：[1]南阳市中心医院肿瘤科,河南南阳473009

出　　处：《中华肿瘤防治杂志》2011年第5期374-376,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:观察分析进展期胃癌术后早期连续腹腔化疗的疗效及毒副反应。方法:对2002-03-2007-03胃癌根治术后的69例进展期患者,早期用腹腔化疗的病例进行回顾性分析,并以同期行静脉化疗的61例患者作对照。分析比较两组患者生存率、复发率和不良反应的差异。结果:腹腔化疗组1、2和3年生存率分别为89.86%、79.71%和65.22%,静脉化疗组1、2和3年生存率分别为77.05%、68.85%和59.01%。而连续腹腔化疗组不良反应(除腹痛、腹胀外)及复发率均低于静脉化疗组。结论:进展期胃癌术后早期腹腔化疗简单实用、安全、全身毒副反应小,可有效预防腹腔内复发和转移,提高术后生存质量和生存率。OBJECTIVE： To evaluate for the therapeutic effect of intraperitoneal chemotherapy for postoperative patients with gastric carcinoma undergoing radical gastrectomy. METHODS： From Mar. 2002 to Mar. 2002, 69 patients with advanced gastric cancer were treated with intraperitoneal chemotherapy after radical gastrectomy. Totally 61 homochronous patients, results with intravenous chemotherapy （IVC） were selected as control. The relapse rate, survival rate and adverse reaction were observed. RESULTS： One, two and three year in intraperitoneal ehemotherapy（IPC） group were 89.86 %, 79.71% and 65.22% respectively, that in IVC group were 77.05%, 68.85 % and 59.01% respectively. Relapse rate and adverse effect except for stomachache and abdominal distension in IPC group were less than those in IVC group. CONCLUSION： For patients with advanced gastric cancer, treatment with IPC at the early period after radical gastrectomy is easily and salty and has less side effect, which can increase survival rate and life quality, effective in preventing relapse in abdomen.

关 键 词：胃肿瘤/药物疗法 疗效 

分 类 号：R735.2[医药卫生—肿瘤]